Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Reply.

Hayward KL, Valery PC, Cottrell WN, Irvine KM, Martin JH, Powell EE.

Hepatol Commun. 2019 Jul 10;3(9):1283-1284. doi: 10.1002/hep4.1398. eCollection 2019 Sep. No abstract available.

2.

Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores.

Patel PJ, Cheng JC, Banh X, Gracen L, Radford-Smith D, Hossain F, Horsfall LU, Hayward KL, Williams S, Johnson T, Brown NN, Saad N, Stuart KA, Russell AW, Valery PC, Clouston AD, Irvine KM, Bernard A, Powell EE.

Clin Gastroenterol Hepatol. 2019 Jul 25. pii: S1542-3565(19)30780-3. doi: 10.1016/j.cgh.2019.07.036. [Epub ahead of print]

PMID:
31352092
3.

Increasing Hospitalization Rates for Cirrhosis: Overrepresentation of Disadvantaged Australians.

Powell EE, Skoien R, Rahman T, Clark PJ, O'Beirne J, Hartel G, Stuart KA, McPhail SM, Gupta R, Boyd P, Valery PC.

EClinicalMedicine. 2019 Jun 13;11:44-53. doi: 10.1016/j.eclinm.2019.05.007. eCollection 2019 May-Jun.

4.

Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation.

Loh Z, Fitzsimmons RL, Reid RC, Ramnath D, Clouston A, Gupta PK, Irvine KM, Powell EE, Schroder K, Stow JL, Sweet MJ, Fairlie DP, Iyer A.

Br J Pharmacol. 2019 Oct;176(19):3775-3790. doi: 10.1111/bph.14768. Epub 2019 Aug 17.

PMID:
31236923
5.

Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis.

Yang YM, Noureddin M, Liu C, Ohashi K, Kim SY, Ramnath D, Powell EE, Sweet MJ, Roh YS, Hsin IF, Deng N, Liu Z, Liang J, Mena E, Shouhed D, Schwabe RF, Jiang D, Lu SC, Noble PW, Seki E.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaat9284. doi: 10.1126/scitranslmed.aat9284.

PMID:
31189722
6.

Engaging primary care clinicians in the assessment of NAFLD.

Valery PC, Powell EE.

Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):458-460. doi: 10.1038/s41575-019-0164-4. No abstract available.

PMID:
31142817
7.

Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention.

Hayward KL, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, Tallis CJ, Stuart KA, Irvine KM, Cottrell WN, Martin JH, Powell EE.

Hepatol Commun. 2019 Mar 18;3(5):620-631. doi: 10.1002/hep4.1334. eCollection 2019 May.

8.

Corrigendum: Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Irvine KM, Ratnasekera I, Powell EE, Hume DA.

Front Immunol. 2019 Apr 9;10:818. doi: 10.3389/fimmu.2019.00818. eCollection 2019.

9.

Causes and Consequences of Innate Immune Dysfunction in Cirrhosis.

Irvine KM, Ratnasekera I, Powell EE, Hume DA.

Front Immunol. 2019 Feb 25;10:293. doi: 10.3389/fimmu.2019.00293. eCollection 2019. Review. Erratum in: Front Immunol. 2019 Apr 09;10:818.

10.

A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care.

Patel P, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Bernard A, Brown NN, Lampe G, Buck L, Saad N, Russell AW, Valery PC, Irvine KM, Clouston AD, Stuart KA, Rosenberg W, Powell EE.

Hepatol Commun. 2018 Aug 6;2(8):893-905. doi: 10.1002/hep4.1208. eCollection 2018 Aug.

11.

Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes.

Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ.

JCI Insight. 2018 Jul 26;3(14). pii: 120274. doi: 10.1172/jci.insight.120274. eCollection 2018 Jul 26.

12.

Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control.

Patel PJ, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, Johnson T, Brown NN, Saad N, Valery PC, Irvine KM, Clouston AD, Stuart KA, Russell AW, Powell EE.

J Diabetes Complications. 2018 Aug;32(8):799-804. doi: 10.1016/j.jdiacomp.2018.05.008. Epub 2018 May 12.

PMID:
29861312
13.

Haemochromatosis: a clinical update for the practising physician.

Radford-Smith DE, Powell EE, Powell LW.

Intern Med J. 2018 May;48(5):509-516. doi: 10.1111/imj.13784. Review.

PMID:
29722188
14.

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.

Patel PJ, Smith D, Connor JP, Horsfall LU, Hayward KL, Hossain F, Williams S, Johnson T, Stuart KA, Brown NN, Saad N, Clouston AD, Irvine KM, Russell AW, Valery PC, Powell EE.

Can J Gastroenterol Hepatol. 2017;2017:7927685. doi: 10.1155/2017/7927685. Epub 2017 Nov 1.

15.

Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis.

Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, Tallis CJ, Stuart KA, Wright PL, Smith DD, Irvine KM, Powell EE, Cottrell WN.

World J Gastroenterol. 2017 Oct 28;23(40):7321-7331. doi: 10.3748/wjg.v23.i40.7321.

16.

Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.

Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, Stuart KA, Brown NN, Saad N, Clouston A, Irvine KM, Russell AW, Valery PC, Williams S, Powell EE.

Intern Med J. 2018 Feb;48(2):144-151. doi: 10.1111/imj.13667.

PMID:
29083080
17.

Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis.

Maradana MR, Yekollu SK, Zeng B, Ellis J, Clouston A, Miller G, Talekar M, Bhuyan ZA, Mahadevaiah S, Powell EE, Irvine KM, Thomas R, O'Sullivan BJ.

Metabolism. 2018 Jan;78:80-94. doi: 10.1016/j.metabol.2017.09.002. Epub 2017 Sep 20.

PMID:
28941597
18.

Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management.

Hayward KL, Horsfall LU, Ruffin BJ, Cottrell WN, Chachay VS, Irvine KM, Martin JH, Powell EE, Valery PC.

Intern Med J. 2017 Aug;47(8):952-955. doi: 10.1111/imj.13505.

PMID:
28782215
19.

Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial.

Hayward KL, Martin JH, Cottrell WN, Karmakar A, Horsfall LU, Patel PJ, Smith DD, Irvine KM, Powell EE, Valery PC.

Trials. 2017 Jul 20;18(1):339. doi: 10.1186/s13063-017-2075-4.

20.

Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.

Patel PJ, Hayward KL, Rudra R, Horsfall LU, Hossain F, Williams S, Johnson T, Brown NN, Saad N, Clouston AD, Stuart KA, Valery PC, Irvine KM, Russell AW, Powell EE.

Medicine (Baltimore). 2017 Jun;96(26):e6761. doi: 10.1097/MD.0000000000006761.

21.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

22.

Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers.

Irvine KM, Wockner LF, Hoffmann I, Horsfall LU, Fagan KJ, Bijin V, Lee B, Clouston AD, Lampe G, Connolly JE, Powell EE.

PLoS One. 2016 Nov 18;11(11):e0167001. doi: 10.1371/journal.pone.0167001. eCollection 2016.

23.

CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.

Irvine KM, Banh X, Gadd VL, Wojcik KK, Ariffin JK, Jose S, Lukowski S, Baillie GJ, Sweet MJ, Powell EE.

JCI Insight. 2016 Jun 2;1(8):e86914. doi: 10.1172/jci.insight.86914.

24.

Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.

Hayward KL, Valery PC, Cottrell WN, Irvine KM, Horsfall LU, Tallis CJ, Chachay VS, Ruffin BJ, Martin JH, Powell EE.

BMC Gastroenterol. 2016 Sep 13;16:114. doi: 10.1186/s12876-016-0530-4.

25.

The toll-like receptor 3 pathway in homeostasis, responses to injury and wound repair.

Ramnath D, Powell EE, Scholz GM, Sweet MJ.

Semin Cell Dev Biol. 2017 Jan;61:22-30. doi: 10.1016/j.semcdb.2016.08.014. Epub 2016 Aug 20. Review.

PMID:
27552920
26.

Identifying areas of need relative to liver disease: geographic clustering within a health service district.

El-Atem N, Irvine KM, Valery PC, Wojcik K, Horsfall L, Johnson T, Janda M, McPhail SM, Powell EE.

Aust Health Rev. 2017 Aug;41(4):407-418. doi: 10.1071/AH15225.

PMID:
27509003
27.

Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation.

Gadd VL, Patel PJ, Jose S, Horsfall L, Powell EE, Irvine KM.

PLoS One. 2016 Jun 16;11(6):e0157771. doi: 10.1371/journal.pone.0157771. eCollection 2016.

28.

Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability.

von Wulffen M, Clark PJ, Macdonald GA, Raj AS, Kendall BJ, Powell EE, Jones MP, Holtmann G.

Aliment Pharmacol Ther. 2016 Jul;44(1):68-77. doi: 10.1111/apt.13657. Epub 2016 May 17.

29.

Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease.

El-Atem NA, Wojcik K, Horsfall L, Irvine KM, Johnson T, McPhail SM, Powell EE.

Intern Med J. 2016 Apr;46(4):420-6. doi: 10.1111/imj.13008.

PMID:
26762655
30.

Spatiotemporal Characterization of the Cellular and Molecular Contributors to Liver Fibrosis in a Murine Hepatotoxic-Injury Model.

Melino M, Gadd VL, Alexander KA, Beattie L, Lineburg KE, Martinez M, Teal B, Le Texier L, Irvine KM, Miller GC, Boyle GM, Hill GR, Clouston AD, Powell EE, MacDonald KP.

Am J Pathol. 2016 Mar;186(3):524-38. doi: 10.1016/j.ajpath.2015.10.029. Epub 2016 Jan 4.

PMID:
26762581
31.

Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury.

Irvine KM, Clouston AD, Gadd VL, Miller GC, Wong WY, Melino M, Maradana MR, MacDonald K, Lang RA, Sweet MJ, Blumenthal A, Powell EE.

Fibrogenesis Tissue Repair. 2015 Oct 15;8:19. doi: 10.1186/s13069-015-0036-7. eCollection 2015.

32.

Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Hayward KL, Powell EE, Irvine KM, Martin JH.

Br J Clin Pharmacol. 2016 Feb;81(2):210-22. doi: 10.1111/bcp.12802. Epub 2015 Dec 25. Review.

33.

The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease.

Irvine KM, Wockner LF, Shanker M, Fagan KJ, Horsfall LU, Fletcher LM, Ungerer JP, Pretorius CJ, Miller GC, Clouston AD, Lampe G, Powell EE.

Liver Int. 2016 Mar;36(3):370-7. doi: 10.1111/liv.12896. Epub 2015 Aug 28.

PMID:
26104018
34.

Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.

Fagan KJ, Rogers GB, Melino M, Arthur DM, Costello ME, Morrison M, Powell EE, Irvine KM.

PLoS One. 2015 Mar 17;10(3):e0120642. doi: 10.1371/journal.pone.0120642. eCollection 2015.

35.

Response to ELF cut-off points: aetiology is also a relevant factor.

Powell EE, Irvine KM, Fagan KJ, Ballard E, O'Rourke P.

Liver Int. 2015 Jul;35(7):1921. doi: 10.1111/liv.12822. Epub 2015 Mar 27. No abstract available.

PMID:
25762021
36.

Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration.

Irvine KM, Skoien R, Bokil NJ, Melino M, Thomas GP, Loo D, Gabrielli B, Hill MM, Sweet MJ, Clouston AD, Powell EE.

World J Gastroenterol. 2014 Dec 21;20(47):17851-62. doi: 10.3748/wjg.v20.i47.17851.

37.

ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity.

Fagan KJ, Pretorius CJ, Horsfall LU, Irvine KM, Wilgen U, Choi K, Fletcher LM, Tate J, Melino M, Nusrat S, Miller GC, Clouston AD, Ballard E, O'Rourke P, Lampe G, Ungerer JP, Powell EE.

Liver Int. 2015 Jun;35(6):1673-81. doi: 10.1111/liv.12760. Epub 2015 Jan 20.

PMID:
25495373
38.

Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?

Fagan KJ, Zhao EY, Horsfall LU, Ruffin BJ, Kruger MS, McPhail SM, O'Rourke P, Ballard E, Irvine KM, Powell EE.

Intern Med J. 2014 Sep;44(9):865-72. doi: 10.1111/imj.12491.

PMID:
24893971
39.

Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers.

Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson L, O'Rourke P, Martin J, Scott I, Pretorius CJ, Ungerer JP, Powell EE.

BMC Gastroenterol. 2014 May 22;14:97. doi: 10.1186/1471-230X-14-97.

40.

The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease.

Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, Irvine K, Clouston AD.

Hepatology. 2014 Apr;59(4):1393-405. doi: 10.1002/hep.26937. Epub 2014 Mar 1.

PMID:
24254368
41.

Wheat straw biomass: a resource for high-value chemicals.

Schnitzer M, Monreal CM, Powell EE.

J Environ Sci Health B. 2014;49(1):51-67. doi: 10.1080/03601234.2013.836924.

PMID:
24138469
42.

Khat-associated hepatitis.

Forbes MP, Raj AS, Martin J, Lampe G, Powell EE.

Med J Aust. 2013 Oct 7;199(7):498-9. No abstract available.

PMID:
24099213
43.

BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin.

Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson LA, Clouston AD, Jonsson JR, O'Rourke P, Martin J, Pretorius CJ, Ungerer JP, Powell EE.

Alcohol Clin Exp Res. 2013 Oct;37(10):1771-8. doi: 10.1111/acer.12143. Epub 2013 Jul 22.

PMID:
23875541
44.

Assessment of alcohol histories obtained from patients with liver disease: opportunities to improve early intervention.

Fagan KJ, Irvine KM, Kumar S, Bates A, Horsfall LU, Feeney GF, Powell EE.

Intern Med J. 2013 Oct;43(10):1096-102. doi: 10.1111/imj.12229.

PMID:
23834077
45.

Use of standardised assessment forms in referrals to hepatology outpatient services: implications for accurate triaging of patients with chronic hepatitis C.

Horsfall L, Macdonald G, Scott I, Skoien R, Khatun M, Moss C, Seligman C, Kardash C, Poxon V, Powell EE.

Aust Health Rev. 2013 May;37(2):218-22. doi: 10.1071/AH12162.

PMID:
23448666
46.

Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.

Skoien R, Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, O'Brien PE, Tilg H, Moschen AR, Baumann U, Brown RM, Couper RT, Manton ND, Ee LC, Weltman M, Clouston AD.

Liver Int. 2013 Apr;33(4):624-32. doi: 10.1111/liv.12100. Epub 2013 Jan 29.

PMID:
23356584
47.

Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C.

Gadd VL, Melino M, Roy S, Horsfall L, O'Rourke P, Williams MR, Irvine KM, Sweet MJ, Jonsson JR, Clouston AD, Powell EE.

Liver Int. 2013 Apr;33(4):569-79. doi: 10.1111/liv.12050. Epub 2012 Dec 13.

PMID:
23240894
48.

Triage of referrals to outpatient hepatology services: an ineffective tool to prioritise patients?

Horsfall L, Skoien R, Moss C, Scott I, Macdonald GA, Powell EE.

Aust Health Rev. 2012 Nov;36(4):443-7. doi: 10.1071/AH11111.

PMID:
23062780
49.

Liver repercussions of defective gut surveillance.

Irvine KM, Schroder K, Powell EE.

Hepatology. 2012 Sep;56(3):1174-7. doi: 10.1002/hep.25944. No abstract available.

PMID:
22930647
50.

Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists.

Bergqvist CJ, Skoien R, Horsfall L, Clouston AD, Jonsson JR, Powell EE.

Intern Med J. 2013 Mar;43(3):247-53. doi: 10.1111/j.1445-5994.2012.02848.x.

PMID:
22646061

Supplemental Content

Loading ...
Support Center